NCT04600947

Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma

A Multicenter, Open-Label, Single-arm Phase II Study of LP002 in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 69 (estimated)
• Sponsor: Taizhou HoudeAoke Biomedical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

LP002 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors. In this study, the efficacy and safety of LP002 for the treatment of relapsed or refractory primary mediastinal large B-cell lymphoma will be evaluated.

Conditions

• Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

Interventions

Type	Name	Description
DRUG	LP002	10 mg/kg administered as IV infusion on Day 1 of each 14-day cycle.

Timeline

• Start date: 2020-12-30
• Primary completion: 2022-05-30
• Completion: 2023-05-30
• First posted: 2020-10-23
• Last updated: 2020-10-23

Locations

7 sites across 1 country: China